» Articles » PMID: 33574663

Predicting Re-Exacerbation Timing and Understanding Prolonged Exacerbations: An Analysis of Patients with COPD in the ECLIPSE Cohort

Overview
Publisher Dove Medical Press
Specialty Pulmonary Medicine
Date 2021 Feb 12
PMID 33574663
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Understanding risk factors for an acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is important for optimizing patient care. We re-analyzed data from the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study (NCT00292552) to identify factors predictive of re-exacerbations and associated with prolonged AECOPDs.

Methods: Patients with COPD from ECLIPSE with moderate/severe AECOPDs were included. The end of the first exacerbation was the index date. Timing of re-exacerbation risk was assessed in patients with 180 days' post-index-date follow-up data. Factors predictive of early (1-90 days) vs late (91-180 days) vs no re-exacerbation were identified using a multivariable partial-proportional-odds-predictive model. Explanatory logistic-regression modeling identified factors associated with prolonged AECOPDs.

Results: Of the 1,554 eligible patients from ECLIPSE, 1,420 had 180 days' follow-up data: more patients experienced early (30.9%) than late (18.7%) re-exacerbations; 50.4% had no re-exacerbation within 180 days. Lower post-bronchodilator FEV (=0.0019), a higher number of moderate/severe exacerbations on/before index date (<0.0001), higher St. George's Respiratory Questionnaire total score (=0.0036), and season of index exacerbation (autumn vs winter, =0.00164) were identified as predictors of early (vs late/none) re-exacerbation risk within 180 days. Similarly, these were all predictors of any (vs none) re-exacerbation risk within 180 days. Median moderate/severe AECOPD duration was 12 days; 22.7% of patients experienced a prolonged AECOPD. The odds of experiencing a prolonged AECOPD were greater for severe vs moderate AECOPDs (adjusted odds ratio=1.917, =0.002) and lower for spring vs winter AECOPDs (adjusted odds ratio=0.578, =0.017).

Conclusion: Prior exacerbation history, reduced lung function, poorer respiratory-related quality-of-life (greater disease burden), and season may help identify patients who will re-exacerbate within 90 days of an AECOPD. Severe AECOPDs and winter AECOPDs are likely to be prolonged and may require close monitoring.

Citing Articles

Risk factors for prolonged hospitalization as a marker for difficult-to-manage exacerbations of chronic obstructive lung disease (COPD): the DiMECO Study.

Esendagli D, Kokturk N, Baha A, Yapar D, Ozkan S, Sen E BMC Pulm Med. 2024; 24(1):590.

PMID: 39609669 PMC: 11605944. DOI: 10.1186/s12890-024-03399-7.


The Effect of Opioids and Benzodiazepines on Exacerbation Rate and Overall Survival in Patients with Chronic Obstructive Pulmonary Disease on Long-Term Non-Invasive Ventilation.

Chai A, Csoma B, Lazar Z, Bentley A, Bikov A J Clin Med. 2024; 13(18).

PMID: 39337111 PMC: 11433445. DOI: 10.3390/jcm13185624.


Blood reflects acute exacerbation risk and inflammation in elderly chronic obstructive pulmonary disease patients.

Liu C, Zhu J, Zhao L, Li G, Sun J, Zhang S Biomark Med. 2024; 18(10-12):513-521.

PMID: 39136445 PMC: 11364060. DOI: 10.1080/17520363.2024.2347199.


Characterising hospitalisation risk for chronic obstructive pulmonary disease exacerbations: Bedside and outpatient clinic assessments of easily measured variables.

Heerema J, Hug S, Bear N, Hill K Chron Respir Dis. 2023; 20:14799731231211852.

PMID: 37934787 PMC: 10631319. DOI: 10.1177/14799731231211852.


Smoking cessation and vaccination.

Montes de Oca M, Laucho-Contreras M Eur Respir Rev. 2023; 32(167).

PMID: 36948500 PMC: 10032588. DOI: 10.1183/16000617.0187-2022.


References
1.
Hurst J, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R . Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010; 363(12):1128-38. DOI: 10.1056/NEJMoa0909883. View

2.
Kotz D, Simpson C, Viechtbauer W, van Schayck O, Sheikh A . Development and validation of a model to predict the 10-year risk of general practitioner-recorded COPD. NPJ Prim Care Respir Med. 2014; 24:14011. PMC: 4373306. DOI: 10.1038/npjpcrm.2014.11. View

3.
Ruparel M, Lopez-Campos J, Castro-Acosta A, Hartl S, Pozo-Rodriguez F, Roberts C . Understanding variation in length of hospital stay for COPD exacerbation: European COPD audit. ERJ Open Res. 2016; 2(1). PMC: 5005149. DOI: 10.1183/23120541.00034-2015. View

4.
. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392(10159):1789-1858. PMC: 6227754. DOI: 10.1016/S0140-6736(18)32279-7. View

5.
Rothnie K, Mullerova H, Smeeth L, Quint J . Natural History of Chronic Obstructive Pulmonary Disease Exacerbations in a General Practice-based Population with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2018; 198(4):464-471. PMC: 6118021. DOI: 10.1164/rccm.201710-2029OC. View